On September 9, 2026 Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, reported that more than 35 abstracts featuring data from its multiple myeloma portfolio will be presented at the 2026 International Myeloma Society (IMS) Annual Meeting in Glasgow, Scotland from September 23 to 26. The presentations span approved and pipeline therapies across multiple stages of disease. They feature long-term follow-up and Phase 3 analyses evaluating outcomes in earlier treatment settings, highlighting advances that contribute to deeper and more durable responses and support the company’s ambition toward potential cures.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Leadership comments on redefining what’s possible for patients with multiple myeloma
"Multiple myeloma treatment has advanced significantly, but our ambition is to keep pushing beyond disease control toward patient outcomes that were once difficult to imagine," said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson. "The breadth of new data at IMS reflect our focus on bringing highly effective therapies into earlier treatment settings, generating long-term follow-up that deepens our understanding of durable responses, and building the scientific understanding needed to further progress potential cures."
Key presentations include:
New ≥ 5-year follow-up from the Phase 2 CARTITUDE-2 Cohort A study evaluating CARVYKTI (ciltacabtagene autoleucel; cilta-cel) as a single infusion in patients with relapsed or refractory multiple myeloma treated as early as second line (1-3 prior lines) (Abstract #PA-288)
New analyses from the Phase 3 MajesTEC-3 study further evaluates overall survival, progression and non-relapse mortality with TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma treated as early as second line (1-3 prior lines), with mixture cure modeling (MCM) estimating >85% statistical cure fractions and suggesting the potential to redefine long-term survival expectations for a substantial proportion of patients (Abstract #OA-49 and Abstract #OA-58)
Results from the Phase 3 MonumenTAL-3 study evaluating TALVEY (talquetamab-tgvs) in combination with DARZALEX FASPRO, with or without pomalidomide, versus DARZALEX FASPRO, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma [Encore of EHA (Free EHA Whitepaper) 2026], as well as results from the Phase 2 MajesTEC-5 TALVEY induction arm evaluating TALVEY plus DARZALEX FASPRO and lenalidomide as induction therapy in transplant-eligible patients with newly diagnosed multiple myeloma. (Abstract #PA-350 and Abstract #OA-51)
Long-term outcomes from the Phase 3 PERSEUS study evaluating DARZALEX FASPRO in a Dara-VRd regimen vs. VRd (bortezomib, lenalidomide and dexamethasone) in transplant-eligible patients with newly diagnosed multiple myeloma (Abstract #LBA-07)
Updated safety and efficacy data for ramantamig (JNJ-5322), an investigational BCMA and GPRC5D trispecific antibody, at the recommended Phase 2 dose, with new data demonstrating feasibility of outpatient dosing in patients with relapsed or refractory multiple myeloma (Abstract #OA-70)
A complete list of Johnson & Johnson–sponsored abstracts is available on JNJ.com.
About Multiple Myeloma
Multiple myeloma is a complex blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.1 In multiple myeloma, these clonal plasma cells proliferate and spread rapidly and replace normal cells in the bone marrow with tumors.2 Multiple myeloma is the second most common blood cancer worldwide.3 More than 180,000 new cases of multiple myeloma are diagnosed globally each year.4 People living with multiple myeloma have a 5-year survival rate of 59.8%.5 While some people diagnosed with multiple myeloma initially have no symptoms, most patients are diagnosed due to symptoms that can include bone fracture or pain, low red blood cell counts, tiredness, high calcium levels and kidney problems or infections.6,7 In recent years, overall survival has improved from years to decades, with effective treatment options now available across every stage and line of therapy.
(Press release, Johnson & Johnson, SEP 9, 2026, View Source [SID1234670668])